Chemical Composition and In Vitro Antiplasmodial Activity of the Ethanolic Extract of Cyperus articulatus var. nodosus Residue

Cyperus articulatus L. is popularly known as priprioca. Its rhizomes are used as a medicine in the treatment of malaria in traditional medicine. Since priprioca oil is extracted for commercial purpose, we evaluated if the components from the priprioca residue can be a source of antiplasmodial active...

Full description

Saved in:
Bibliographic Details
Published in:Pathogens (Basel) 2020-10, Vol.9 (11), p.889
Main Authors: Assis, Francisco Flávio Vieira de, Silva, Nazaré Carneiro da, Moraes, Waldiney Pires, Barata, Lauro Euclides Soares, Minervino, Antonio Humberto Hamad
Format: Article
Language:English
Subjects:
antimalarial
Antiprotozoal agents
Aquatic plants
Blood
Brief Report
Chemical composition
Cyperus articulatus
Cytotoxicity
Extraction
Malaria
Medicine
Metabolites
Oils & fats
Parasitic diseases
phytotherapic
priprioca
Residues
Rhizomes
Sensors
Toxicity
Vector-borne diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cyperus articulatus L. is popularly known as priprioca. Its rhizomes are used as a medicine in the treatment of malaria in traditional medicine. Since priprioca oil is extracted for commercial purpose, we evaluated if the components from the priprioca residue can be a source of antiplasmodial active molecules. This study aimed to determine the in vitro antiplasmodial and cytotoxicity activities of the ethanolic extract of C. articulatus as an in vitro antiplasmodial agent. From the solid residue of the plant rhizomes, 40 g samples were removed and subjected to hot extraction using a Soxhlet extractor. The in vitro antiplasmodial activity was determined using the W2 and 3D7 strains of P. falciparum. The phytochemical study identified the following main compounds: corymbolone (14.25%), cyclocolorenone (9.75%), and cadalene (8.36%). The extract exhibited moderate IC50 (inhibitory concentration) against the two strains of P. falciparum: 1.21 ± 0.01 against the W2 strain and 1.10 ± 0.06 µg/mL against the 3D7 strain. Our results show the therapeutic potential of priprioca residue as a low-cost antiplasmodial agent.
ISSN:2076-0817
2076-0817
DOI:10.3390/pathogens9110889